Sturgiss Elizabeth A, Jin Fengyi, Martin Sarah J, Grulich Andrew, Bowden Francis J
Canberra Sexual Health Centre, The Canberra Hospital, Garran, ACT, Australia.
Sex Health. 2010 Mar;7(1):55-9. doi: 10.1071/SH09023.
Anogenital warts are a common initial presentation to the Canberra Sexual Health Centre. It is anticipated that the introduction of human papillomavirus vaccination will reduce the incidence of anogenital warts. The present study determines the prevalence of other sexually transmissible infections in patients newly diagnosed with warts who may not have presented for screening without the impetus of a genital lump.
The prevalence of other sexually transmissible infections in new patients presenting to the Canberra Sexual Health Centre diagnosed with anogenital warts was determined from a retrospective clinical audit from 2002 to 2007.
A total of 1015 new patients were diagnosed with anogenital warts. Of this total cohort, 53 (5.2%) were found to be co-infected with either chlamydia and/or gonorrhoea. Only 13.2% of co-infected patients reported symptoms other than genital lumps. Of co-infected patients 11.3% reported contact with a partner with chlamydia and/or gonorrhoea. Not all patients were screened for other sexually transmissible infections: 762 (75.1%) were screened for chlamydia and 576 (56.7%) were screened for gonorrhoea. Of those tested, 6.8% of men and 6.9% of women were positive for chlamydia highlighting the importance of offering full sexually transmissible infection screening in those newly diagnosed with anogenital warts. Chlamydia was more common in younger patients who reported a higher number of sexual partners.
It is anticipated that human papillomavirus vaccination will lead to a decline in anogenital wart incidence as well as other human papillomavirus associated disease. Although one opportunity for testing for other sexually transmissible infections may be lost in this population, the decrease in anogenital warts will leave clinicians with more time to pursue other screening programs. Education and screening campaigns should continue to focus on the asymptomatic nature of the majority of sexually transmissible infections.
肛门生殖器疣是堪培拉性健康中心常见的初诊疾病。预计人乳头瘤病毒疫苗的引入将降低肛门生殖器疣的发病率。本研究确定了新诊断为疣的患者中其他性传播感染的患病率,这些患者若没有生殖器肿物的促使可能不会前来筛查。
通过对2002年至2007年的回顾性临床审计,确定在堪培拉性健康中心新诊断为肛门生殖器疣的患者中其他性传播感染的患病率。
共有1015名新患者被诊断为肛门生殖器疣。在整个队列中,发现53例(5.2%)同时感染了衣原体和/或淋病。只有13.2%的合并感染患者报告了除生殖器肿物以外的症状。在合并感染的患者中,11.3%报告与衣原体和/或淋病患者有过接触。并非所有患者都接受了其他性传播感染的筛查:762例(75.1%)接受了衣原体筛查,576例(56.7%)接受了淋病筛查。在接受检测的患者中,6.8%的男性和6.9%的女性衣原体检测呈阳性,这凸显了对新诊断为肛门生殖器疣的患者进行全面性传播感染筛查的重要性。衣原体在报告性伴侣数量较多的年轻患者中更为常见。
预计人乳头瘤病毒疫苗将导致肛门生殖器疣发病率以及其他与人乳头瘤病毒相关疾病的下降。虽然在这一人群中可能会失去一次检测其他性传播感染的机会,但肛门生殖器疣的减少将使临床医生有更多时间开展其他筛查项目。教育和筛查活动应继续关注大多数性传播感染的无症状性。